Fig. 4: DYRK1A is required for KMT2A-R ALL cell proliferation. | Leukemia

Fig. 4: DYRK1A is required for KMT2A-R ALL cell proliferation.

From: DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition

Fig. 4

A Molecular structure of EHT161040. BKMT2A::AFF1 (dark blue; SEM and RS4;11), KMT2A::MLLT1 (light blue; HB11;19 and KOPN8), and non-KMT2A-R ALL cell lines (red; MN60 and Tanoue) were treated with increasing concentrations of EHT161040. Viability/cell proliferation was determined via an XTT assay after 72 h. C Cell cycle analysis of the indicated KMT2A-R ALL cell lines after treatment with 5 µM EHT1610 for 72 h. On the left are representative examples of the flow cytometric analysis (n = 3), and on the right is the summary of all three experiments. D Cell viability and apoptosis were tested in control- and DYRK1A inhibitor-treated (EHT1610; 5 µM; 72 h) KMT2A-R ALL. On the left are representative examples of the flow cytometric analysis (n = 3) and on the right is the summary of all three experiments. Data are represented as individual values with mean ± SEM bars. *P < 0.05; **P < 0.01; ***P < 0.001 by t-test.

Back to article page